Neuroprotective effect of secukinumab against rotenone induced Parkinson's disease in rat model: Involvement of IL-17, HMGB-1/TLR4 axis and BDNF/TrKB cascade.

Mohamed, Yara T; Salama, Abeer; Rabie, Mostafa A; Abd El Fattah, Mai A

Mohamed, Yara T; Salama, Abeer; Rabie, Mostafa A; Abd El Fattah, Mai A.

Afiliação

Mohamed YT; Maintenance & Calibration unit, Technical Support Department, National Organization of Research & Biologicals, Egyptian Drug Authority, Giza, Egypt.
Salama A; Department of Pharmacology, National Research Centre, 33 El Buhouth St., Dokki, Cairo, 12622, Egypt.
Rabie MA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Electronic address: Mostafa.mohammed@pharma.cu.edu.eg.
Abd El Fattah MA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

Int Immunopharmacol ; 114: 109571, 2023 Jan.

Article em En | MEDLINE | ID: mdl-36527875

Assuntos

Fármacos Neuroprotetores; Doença de Parkinson; Ratos; Animais; Doença de Parkinson/patologia; Rotenona; Fármacos Neuroprotetores/uso terapêutico; Fármacos Neuroprotetores/farmacologia; Interleucina-17; Fator Neurotrófico Derivado do Encéfalo; Receptor 4 Toll-Like; Proteínas Proto-Oncogênicas c-akt; Receptor trkB; Ratos Wistar; Proteínas HMGB

Palavras-chave

BDNF; IL-17 receptor; Neuroinflammation; Secukinumab; TLR-4; TrKB

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Fármacos Neuroprotetores Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google